Skip to content
value.today
Hologic, Inc. logo

Hologic, Inc.

HOLXUnlisted company
$16.9 Blast known market cap, Mar 2026 — no current value
Compare
World rank
—
no current market cap
Revenue
$4.1 B
For year ending September-2025
Net income
$566 M
13.8% margin
SEC filing
Employees
6,944
As on 2022
value.today research

Hologic, Inc. in brief

Hologic, Inc. is an unlisted company in the Medical Instruments industry, based in Marlborough, Massachusetts, USA. It was founded in 1985. In the year to September 2025 it had sales of $4.1 B and a net profit of $566 M, about 14 cents of profit for every dollar of sales. It employs about 6,944 people and Stephen P. MacMillan is its chief executive. Its largest product and service lines by sales in 2025 were Disposables (64%), Molecular Diagnostics (32%) and Breast Imaging (27%). By market, the largest shares of its 2025 sales came from USA (74%), Europe (14%) and Asia-Pacific (6%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Hologic, Inc.

Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.

The company was acquired by Blackstone and TPG in 2026.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Hologic, Inc. timeline

9 events, 1985–2026
  1. 1985
  2. 🏁
    · approximate
    Founded
  3. 1994
  4. 🔔
    · approximate
    Initial public offering on Nasdaq as HOLX
  5. 1995
  6. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  7. 2008
  8. 💰
    Revenue passed $1 billion
    FY2008 revenue of $1.7 billion, up from $738 million in FY2007.
  9. 2013
  10. •
    Legal Entity Identifier issued
    LEI 549300DYP6F5ZJL0LB74 registered.
  11. 2021
  12. 💰
    Record revenue of $5.6 billion
    FY2021, the highest of the 19 years on record.
  13. 💰
    Record net income of $1.9 billion
    FY2021, the highest profit of the 12 years on record.
  14. 🏆
    Entered the world's top 1,000 companies by market cap
    Ranked #973 with $18.7 billion on 1 January 2021, up from #1,122 on 1 January 2020.
  15. 2026
  16. 🏆
    Entered the world's top 500 companies by market cap
    Ranked #312 with $16.9 billion on 8 March 2026, up from #1,025 on 5 January 2024.

Events of Hologic, Inc. from Wikidata, SEC EDGAR, the company's financial years, the GLEIF LEI register and our market-cap rankings. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Hologic, Inc.

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 7 April 2026 (Form 8-K).

Market cap history

$0 M$5.4 B$10.7 B$16.1 B$21.5 B2020202120222023202420252026

World rank over time

▲ up 810 places since 2020
2020-01-01: #1122#1,12220202021-01-01: #973#97320212022-01-07: #1159#1,15920222022-12-25: #888#88820222023-07-30: #932#93220232024-01-05: #1025#1,02520242026-03-08: #312#3122026

Rank in USA: #435 (Jan 2020) · #388 (Jan 2021) · #483 (Jan 2022) · #359 (Dec 2022) · #386 (Jul 2023) · #410 (Jan 2024) · #7 (Mar 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
13.2%
Operating margin
17.4%
Return on equity
10.8%
Liabilities / assets
44.0%
Net debt
$548M
Revenue growth
+1.7%
R&D / revenue
6.1%
Revenue per employee
$591 K
Profit per employee
$81 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $3.2B, net income $-111M$3.2BFY18Fiscal year ending Sep 2019: revenue $3.4B, net income $-204M$3.4BFY19Fiscal year ending Sep 2020: revenue $3.8B, net income $1.1B$3.8BFY20Fiscal year ending Sep 2021: revenue $5.6B, net income $1.9B$5.6BFY21Fiscal year ending Sep 2022: revenue $4.9B, net income $1.3B$4.9BFY22Fiscal year ending Sep 2023: revenue $4.0B, net income $456M$4.0BFY23Fiscal year ending Sep 2024: revenue $4.0B, net income $790M$4.0BFY24Fiscal year ending Sep 2025: revenue $4.1B, net income $566M$4.1BFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025$4.1B+1.7%$714M$566M13.8%
Sep 2024$4.0B-0.0%$883M$790M19.6%
Sep 2023$4.0B-17.1%$668M$456M11.3%
Sep 2022$4.9B-13.7%$1.6B$1.3B26.8%
Sep 2021$5.6B+49.1%$2.5B$1.9B33.2%
Sep 2020$3.8B+12.1%$1.1B$1.1B29.5%
Sep 2019$3.4B+4.6%$-124M$-204M-6.0%
Sep 2018$3.2B—$-238M$-111M-3.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$1.1B$59M$998M$2.49—
Sep 2024$1.3B$72M$1.2B$3.32—
Sep 2023$1.1B$92M$959M$1.83—
Sep 2022$2.1B$71M$2.1B$5.13—
Sep 2021$2.3B$118M$2.2B$7.21—
Sep 2020$897M$98M$798M$4.21—
Sep 2019$650M$57M$593M$-0.76—
Sep 2018$733M$58M$675M$-0.40—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$4.1B
Net income, trailing 12 months
$544M
RevenueNet income
Three months to Mar 2024: revenue $1.0B, net income $170M$1.0BMar ’24Three months to Jun 2024: revenue $1.0B, net income $195M$1.0BJun ’24Three months to Sep 2024: revenue —, net income $179M—Sep ’24Three months to Dec 2024: revenue $1.0B, net income $201M$1.0BDec ’24Three months to Mar 2025: revenue $1.0B, net income $-17M$1.0BMar ’25Three months to Jun 2025: revenue $1.0B, net income $195M$1.0BJun ’25Three months to Sep 2025: revenue —, net income $187M—Sep ’25Three months to Dec 2025: revenue $1.0B, net income $179M$1.0BDec ’25

Latest quarter to Dec 2025: revenue $1.0B (+2.5% on a year earlier), net income $179M. Trailing 12 months to Dec 2025.

SEC filings

Official filings of Hologic, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$4.1 B
Operating income
$714 M
Net income
$566 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$9.0 B
Total liabilities
$4.0 B
Total equity
$5.0 B

As of September-2025

HOLOGIC - Yearly Revenue and Net Income - in Million USD

Year - EndingRevenueOperating IncomeNet Income
Sep-20224,8621,6301,302
Sep-20215,6322,4821,871
Sep-20203,7761,1241,115
Sep-20193,367-10-203
Sep-20183,218508-111

HOLOGIC - Quarterly Results Summary - in Million USD

Quarterly Ending:Total RevenueOperating IncomeNet Income
Dec-20221,074263187
Sep-2022953170118
Jun-20221,002229228
Mar-20221,435594455
Dec-20211,471637499
Sep-20211,316445328
Jun-20211,168362268

Balance sheet

Total Assets as on Sep-2022 was 9,071 Million USD.

Total Liabilities as on Sep-2022 was 4,195 Million USD.

Total Equity as on Sep-2022 was 4,876 Million USD.

Top 4 institutional investors in Hologic, Inc.#

As of Jun 30, 2026
4 institutions held 1.5 M shares on Jun 30, 2026. Source: SEC Form 13F filings, filed through Aug 13, 2026. Change is since the previous quarter.
The 4 largest institutional investors in Hologic, Inc.
#InstitutionShares heldChange (shares)ValueFiled
1DekaBank Deutsche Girozentrale1,475,3790 (0.00%)$112 MAug 5, 2026
2Mizuho Securities USA LLC13,4550 (0.00%)$1 MJul 24, 2026
3IFP Advisors, Inc54-33 (-37.93%)$0 MJul 20, 2026
4Huntington National Bank1-404 (-99.75%)$0 MAug 13, 2026

Mutual funds holding Hologic, Inc.#

135 funds in 2 countries hold shares worth $4 M. Since their previous reports 29 added shares and 258 sold, selling $2.2 B net. By country: USA 118 ($4 M), Sweden 17 ($0 M).
Mutual funds holding Hologic, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 AltShares Merger Arbitrage ETFWater Island Capital, LLC38,727$3 M—2.8%—Feb 28, 2026
🇺🇸 AQR Large Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC7,943$1 M—0.11%—Mar 31, 2026
🇺🇸 Vanguard 500 Index FundThe Vanguard Group, Inc.5.70 M$0 M—<0.01%+0.8%Jun 30, 2026
🇺🇸 The Merger FundVirtus Investment Advisers, LLC375,385$0 M—<0.01%+0.2%Jun 30, 2026
🇺🇸 BlackRock Event Driven Equity FundBlackRock Advisors, LLC1.77 M$0 M—<0.01%no changeMay 29, 2026
🇺🇸 Nexpoint Merger Arbitrage FundNexPoint Asset Management, L.P.1.47 M$0 M—<0.01%+1.2%Jun 30, 2026
🇺🇸 Vanguard Institutional Index FundThe Vanguard Group, Inc.1.25 M$0 M—<0.01%−0.1%Jun 30, 2026
🇺🇸 iShares U.S. Medical Devices ETFBlackRock Fund Advisors970,066$0 M—<0.01%+1.3%Jun 30, 2026
🇺🇸 iShares Russell 1000 Value ETFBlackRock Fund Advisors515,257$0 M—<0.01%+0.7%Jun 30, 2026
🇺🇸 iShares S&P 500 Value ETFBlackRock Fund Advisors381,105$0 M—<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Mid-Cap Value ETFBlackRock Fund Advisors318,653$0 M—<0.01%−0.6%Jun 30, 2026
🇺🇸 Fidelity SAI Merger Arbitrage FundFidelity Diversifying Solutions LLC295,581$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares ESG Aware MSCI USA ETFBlackRock Fund Advisors207,094$0 M—<0.01%−1.3%May 31, 2026
🇺🇸 iShares Core S&P U.S. Value ETFBlackRock Fund Advisors189,837$0 M—<0.01%+1.9%Jun 30, 2026
🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc.170,622$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP168,658$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.162,940$0 M—<0.01%−2.4%May 31, 2026
🇺🇸 iShares Russell 1000 ETFBlackRock Fund Advisors157,405$0 M—<0.01%−0.6%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC138,368$0 M—<0.01%no changeMay 29, 2026
🇺🇸 iShares U.S. Healthcare ETFBlackRock Fund Advisors117,311$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares Global Healthcare ETFBlackRock Fund Advisors105,133$0 M—<0.01%−0.1%Jun 30, 2026
🇸🇪 Storebrand Global SolutionsStorebrand Asset Management AS109,052$0 M—0%no changeJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC100,790$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares MSCI Global Min Vol Factor ETFBlackRock Fund Advisors92,622$0 M—<0.01%−2.5%May 31, 2026
🇺🇸 iShares MSCI ACWI ETFBlackRock Fund Advisors72,235$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors61,706$0 M—<0.01%+1.2%Jun 30, 2026
🇺🇸 500 Index TrustJohn Hancock Variable Trust Advisers LLC45,668$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Equity Index PortfolioThe Vanguard Group, Inc.50,007$0 M—<0.01%+0.7%Jun 30, 2026
🇺🇸 Victory 500 Index FundVictory Capital Management Inc.52,689$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares MSCI USA Equal Weighted ETFBlackRock Fund Advisors39,320$0 M—<0.01%+4.7%May 31, 2026
🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC41,299$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Ftse Social Index FundThe Vanguard Group, Inc.28,338$0 M—<0.01%−2.9%May 31, 2026
🇺🇸 Vanguard Russell 1000 Value Index FundThe Vanguard Group, Inc.32,822$0 M—<0.01%+1.3%May 31, 2026
🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust30,570$0 M—<0.01%+1.2%May 31, 2026
🇺🇸 Fidelity Enhanced Mid Cap Core ETFFidelity Management & Research Company LLC29,948$0 M—<0.01%+1.0%Jun 30, 2026
🇺🇸 Vanguard Tax-Managed Capital Appreciation FundThe Vanguard Group, Inc.26,958$0 M—<0.01%−76%Jun 30, 2026
🇺🇸 Vanguard Tax-Managed Balanced FundThe Vanguard Group, Inc.29,853$0 M—<0.01%no changeJun 30, 2026
🇺🇸 The Gabelli ABC FundGabelli Funds, LLC27,500$0 M—<0.01%+45%Jun 30, 2026
🇺🇸 Bridge Builder Tax Managed Large Cap FundOLIVE STREET INVESTMENT ADVISERS LLC27,432$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Six Circles Managed Equity Portfolio U.S. Unconstrained FundJ.P. Morgan Private Investments Inc.30,615$0 M—<0.01%no changeJun 30, 2026
🇺🇸 JNL Multi-Manager Alternative FundJackson National Asset Management, LLC25,712$0 M—<0.01%+0.1%Jun 30, 2026
🇺🇸 iShares Morningstar Mid-Cap Value ETFBlackRock Fund Advisors31,250$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares ESG MSCI KLD 400 ETFBlackRock Fund Advisors34,443$0 M—<0.01%no changeJul 31, 2026
🇸🇪 Storebrand Global PlusStorebrand Asset Management AS29,379$0 M—0%no changeJun 30, 2026
🇺🇸 iShares MSCI World ETFBlackRock Fund Advisors22,670$0 M—<0.01%+15%May 31, 2026
🇺🇸 U.S. Sector Rotation FundJohn Hancock Investment Management LLC17,868$0 M—<0.01%−2.5%May 31, 2026
🇺🇸 Siit S&P 500 Index FundSEI INVESTMENTS MANAGEMENT CORPORATION16,529$0 M—<0.01%no changeMay 31, 2026
🇺🇸 AVIP Intech U.S. Low Volatility PortfolioCONSTELLATION INVESTMENTS INC20,491$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Praxis Small Cap Index FundPraxis Investment Management, Inc.11,418$0 M—<0.01%+20%Jun 30, 2026
🇺🇸 Calvert U.S. Large Cap Core Responsible Index FundCalvert Research and Management23,929$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP16,873$0 M—<0.01%no changeJul 31, 2026
🇸🇪 Storebrand USAStorebrand Asset Management AS17,346$0 M—0%no changeJun 30, 2026
🇸🇪 Storebrand Global All CountriesStorebrand Asset Management AS15,467$0 M—0%no changeJun 30, 2026
🇺🇸 Xtrackers Russell US Multifactor ETFDBX Advisors LLC5,269$0 M—<0.01%+9.8%May 29, 2026
🇺🇸 Vanguard Esg U.S. Stock ETFThe Vanguard Group, Inc.12,264$0 M—<0.01%−0.1%May 31, 2026
🇺🇸 Vanguard S&P 500 Value Index FundThe Vanguard Group, Inc.12,575$0 M—<0.01%−1.4%May 31, 2026
🇺🇸 Global Multi-Strategy FundPrincipal Global Investors, LLC12,804$0 M—<0.01%+4.1%May 31, 2026
🇺🇸 Morgan Stanley Pathway Large Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC8,597$0 M—<0.01%+2.0%May 31, 2026
🇺🇸 iShares ESG Advanced MSCI USA ETFBlackRock Fund Advisors11,769$0 M—<0.01%−0.9%May 31, 2026
🇺🇸 iShares ESG MSCI USA Leaders ETFBlackRock Fund Advisors7,368$0 M—<0.01%−1.2%May 31, 2026
🇺🇸 Vanguard Russell 1000 Index FundThe Vanguard Group, Inc.9,210$0 M—<0.01%−1.6%May 31, 2026
🇺🇸 Avantis U.S. Mid Cap Equity ETFAmerican Century ETF Trust8,128$0 M—<0.01%+3.2%May 31, 2026
🇺🇸 Siit Large Cap Index FundSEI INVESTMENTS MANAGEMENT CORPORATION6,700$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Siit Dynamic Asset Allocation FundSEI INVESTMENTS MANAGEMENT CORPORATION5,629$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC9,368$0 M—<0.01%−8.9%Jun 30, 2026
🇺🇸 Franklin U.S. Equity Index ETFFranklin Advisory Services, LLC6,369$0 M—<0.01%+7.4%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC6,157$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Large Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC9,569$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Six Circles U.S. Unconstrained Equity FundJ.P. Morgan Private Investments Inc.5,424$0 M—<0.01%no changeJun 30, 2026
🇺🇸 AZL S&P 500 Index FundAllianz Investment Management LLC9,748$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Calvert U.S. Large Cap Value Responsible Index FundCalvert Research and Management10,479$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Calvert U.S. Mid Cap Core Responsible Index FundCalvert Research and Management9,625$0 M—<0.01%no changeJun 30, 2026
🇺🇸 iShares Morningstar Value ETFBlackRock Fund Advisors8,671$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares Dow Jones U.S. ETFBlackRock Fund Advisors9,405$0 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares MSCI USA Size Factor ETFBlackRock Fund Advisors10,133$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP14,057$0 M—<0.01%no changeJul 31, 2026
🇸🇪 SPP Generation 60-talStorebrand Asset Management AS10,257$0 M—0%+16%Jun 30, 2026
🇸🇪 SPP Generation 70-talStorebrand Asset Management AS8,280$0 M—0%no changeJun 30, 2026
🇸🇪 SEB USA ExposureSEB Funds AB12,259$0 M—0%no changeJun 30, 2026
🇺🇸 Xtrackers MSCI USA Selection Equity ETFDBX Advisors LLC3,757$0 M—<0.01%−5.4%May 29, 2026
🇺🇸 Xtrackers MSCI Kokusai Equity ETFDBX Advisors LLC2,087$0 M—<0.01%+1.7%May 29, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,225$0 M—<0.01%no changeMay 31, 2026
🇺🇸 iShares ESG Aware MSCI USA Value ETFBlackRock Fund Advisors4,002$0 M—<0.01%+6.7%May 31, 2026
🇺🇸 Victory Growth and Tax Strategy FundVictory Capital Management Inc.1,784$0 M—<0.01%+55%May 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.4,494$0 M—<0.01%−0.1%May 31, 2026
🇺🇸 Invesco Equally-Weighted S&P 500 FundInvesco Advisers, Inc.179,059$0 M—<0.01%+0.5%May 31, 2026
🇺🇸 Invesco S&P 500 Index FundInvesco Advisers, Inc.15,799$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Column Mid Cap FundTrust for Professional Managers3,968$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Avantis Responsible U.S. Equity ETFAmerican Century ETF Trust1,707$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Equity FundAmerican Century ETF Trust1,983$0 M—<0.01%−41%May 31, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust229$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Large Cap Equity ETFAmerican Century ETF Trust4,921$0 M—<0.01%+3.8%May 31, 2026
🇺🇸 Catholic Values Equity FundSEI INVESTMENTS MANAGEMENT CORPORATION1,306$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Siit Multi-Asset Real Return FundSEI INVESTMENTS MANAGEMENT CORPORATION1,877$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.97$0 M—<0.01%−100%Jun 30, 2026
🇺🇸 AVIP AB Mid Cap Core PortfolioCONSTELLATION INVESTMENTS INC1,110$0 M—<0.01%—Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC3,384$0 M—<0.01%−2.7%Jun 30, 2026
🇺🇸 Thrivent Large Cap Index PortfolioThrivent Financial for Lutherans8,425$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Invesco V.I. Equally-Weighted S&P 500 FundInvesco Advisers, Inc.12,505$0 M—<0.01%+1.1%Jun 30, 2026
🇺🇸 Penn Series Index 500 FundPenn Mutual Asset Management, LLC3,503$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Hologic, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
57
since
$301 K-$9.3 M$0Nov 2023: bought $0 (0 trades), sold $3.9 M (2 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $687 K (1 trades)Jan 2024: bought $0 (0 trades), sold $2.3 M (2 trades)Jan 24Mar 2024: bought $0 (0 trades), sold $2.0 M (3 trades)Jul 2024: bought $0 (0 trades), sold $4.6 M (5 trades)JulAug 2024: bought $0 (0 trades), sold $4.7 M (3 trades)Dec 2024: bought $0 (0 trades), sold $1.9 M (1 trades)DecMay 2025: bought $301 K (1 trades), sold $0 (0 trades)Sep 2025: bought $0 (0 trades), sold $9.3 M (3 trades)SepOct 2025: bought $0 (0 trades), sold $541 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Hologic, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jennifer M. SchneidersPresident, Diag. SolutionsDisposal to the company-41,462——0Form 4
filed Anne M. LiddyGeneral CounselDisposal to the company-28,052——0Form 4
filed Christiana StamoulisDirectorDisposal to the company-50,526——0Form 4
filed Brandon SchnittkerPresident, GYN SurgicalDisposal to the company-17,644——0Form 4
filed Essex D. MitchellChief Operating OfficerDisposal to the company-77,694——0Form 4
filed Karleen Marie ObertonChief Financial OfficerDisposal to the company-150,735——0Form 4
filed Amy McBride WendellDirectorDisposal to the company-25,784——0Form 4
filed Martin D. MadausDirectorDisposal to the company-5,396——0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Ownership and subsidiaries

Source: GLEIF

Markets and events: Hologic, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2025
$0M
Q1 2026
Hologic, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2025Q1 2026$0M
Q3 2025Q4 2025$0M
Q2 2025Q3 2025$35.6M
Q1 2025Q2 2025$200M
Q4 2024Q1 2025$517.3M
Q3 2024Q4 2024$58.3M
Q2 2024Q3 2024$100M
Q1 2024Q2 2024$0M
Q4 2023Q1 2024$676.8M
Q3 2023Q4 2023$211.2M
Q3 2023Q3 2023$113.6M
Q2 2023Q2 2023$50M
Q4 2022Q1 2023$100M
Q3 2022Q4 2022$175.1M
Q2 2022Q3 2022$0M
Q1 2022Q2 2022$200M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Hologic, Inc. scorecard#

Passes 11 of the 18 checks that could be worked out: strongest in financial health (4 of 4), weakest in growth (1 of 6). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 6
    • ✓Revenue grew in the newest year1.7%Revenue up 1.7% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-5.5%-5.5% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-5.5%-5.5% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year2.49 vs 3.32Diluted EPS 2.49 in fiscal 2025 against 3.32 the year before (report's currency).
    • ✗Net income higher than five years earlier$566 M$566 M in fiscal 2025 against $1.1 B in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability4 of 6
    • ✓Profitable in the newest year$566 MNet income $566 M in fiscal 2025.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median17.4%17.4% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%11.1%11.1% in fiscal 2025.
    • ✓Return on invested capital above 10%10.7%10.7% in fiscal 2025.
    • ✗Operating margin wider than three years earlier17.4%17.4% in fiscal 2025 against 33.7% in 2022.
  • Financial health4 of 4
    • ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.75 at the end of fiscal 2025.
    • ✓Debt below equity0.5×Debt to equity 0.50 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDA0.5×Net debt 0.5 times EBITDA in fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns2 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-4.2%Diluted shares down 4.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • ✓Free cash flow covers dividends and buybacks$998 MFree cash flow $998 M against $753 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Hologic, Inc.'s statements, beside the median of Medical Instruments.

Hologic, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin17.4%7.2%
Net margin13.8%3.8%
Return on equity11.1%3.5%
Revenue growth, 3 years a year-5.5%5.0%
Revenue growth1.7%8.9%
Debt to equity0.50×0.46×

6of 9on the Piotroski tests of financial strength

  • Free cash flow has been positive 8 years in a row.
  • The share count fell 4.2% in the year (buybacks).

Hologic, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Hologic, Inc.: statements by fiscal year
PeriodTrendFY 2025to Sep 27, 2025FY 2024to Sep 28, 2024FY 2023to Sep 30, 2023FY 2022to Sep 24, 2022FY 2021to Sep 25, 2021FY 2020to Sep 26, 2020FY 2019to Sep 28, 2019FY 2018to Sep 29, 2018FY 2017to Sep 30, 2017FY 2016to Sep 24, 2016
Income statement
Revenue4,1014,0304,0304,8635,6323,7763,3673,2183,0592,833
Cost of revenue1,5991,5711,549————887882757
Gross profit2,1182,2282,0722,9973,7962,2281,1711,6971,6211,563
Research and development248273294283276223232219233232
Selling and marketing621585595630561485565545499415
General and administrative449409392408433356r332366343267
Operating expenses1,4041,3451,4031,3571,3161,1231,2951,9352511,015
Operating income7148836681,6402,4801,105−124−2381,370549
Interest and finance income74109121131.44.34.66.33.80.7
Interest expense and finance costs1171221119594117141149153155
Other non-operating income (expense)9.6−4.1−1.731−5.49.13.17.61327
Income before tax6818656761,5882,3611,002−258−4191,231415
Income tax11676220286491−109−54−30747585
Net income including minority interests5667904561,3021,8701,111−204−111——
Minority interests' share of net income——00−1.8—————
Net income attributable to shareholders5667904561,3021,8721,115−204−111756331
Earnings per share, basic2.503.351.855.187.284.24-0.76-0.402.701.18
Earnings per share, diluted2.493.321.835.137.214.21-0.76-0.402.641.16
Shares, weighted average (basic)226236247252257263269275280280
Shares, weighted average (diluted)228238249254260265269275286286
Balance sheet
Cash and cash equivalents1,9602,1602,7232,3401,170701602667541548
Short-term investments2431730——————0
Receivables6016006266189431,029649579534447
Inventory679680618624501395445384332275
Other current assets1521561752325295963———
Current assets3,6683,8234,1853,8623,1692,2221,7931,7231,4791,327
Property, plant and equipment560538517482565492471478473r452r
Right-of-use (leased) assets9492636984810———
Goodwill3,6413,4433,2813,2373,2822,6582,5642,5333,1712,803
Other intangible assets5898458891,2811,6591,3081,4602,3992,772r2,643
Long-term investments0960———————
Total assets9,0159,1569,1399,0718,9207,1966,4427,2317,9807,317
Accounts payable193204175198216179187192167157
Debt due within a year2.938287153133252716001,151296
Current liabilities9771,0371,2079381,3271,2391,0701,4031,866902
Long-term debt2,5052,4972,5312,8082,7122,7142,7842,7052,1723,049
Lease liabilities (non-current)7984475466660———
Retained earnings3,4122,8462,0561,600298−1,573−2,689−2,494−2,383−3,138
Shareholders' equity5,0485,1305,0174,8764,2192,7052,1162,4292,7852,143
Minority interests————02.10———
Total equity5,0485,1305,0174,8764,2192,7072,1162,4292,785—
Total liabilities and equity9,0159,1569,1399,0718,9207,1966,4427,2317,9807,317
Cash-flow statement
Depreciation and amortization300309323430407376463480449465
Share-based compensation84828067658362656865
Cash from operating activities1,0571,2851,0512,1262,3308976507338.3798r
Capital expenditure−59−72−92−71−118r−98−57−58−58−47
Intangible assets bought−15−1000−6.50−4.50——
Acquisitions, net of cash acquired−322−297−5.0−159−1,165−119−111−77−1,5580
Cash from investing activities−483−781−152−206−1,330−142−281−195286−68
Debt issued—————————0
Debt repaid——————−1,463−1,359−84−75
Shares bought back−753−835−475−542−410−654−200−276−200−250
Cash from financing activities−777−1,109−483−756−530−660−432−405−309−671r
Exchange-rate effect on cash2.18.90.35.8−1.74.1−2.2−6.87.3−2.0
Change in cash−201−5964161,16946999−65126−7.857
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 27, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Hologic, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$3.3 B79%
  • Disposables$2.6 B64%
  • Molecular Diagnostics$1.3 B32%
  • Breast Imaging$1.1 B27%
  • Service(total)$844 M21%
  • Capital equipment, components and software$638 M16%
  • Cytology & Perinatal$489 M12%
  • Interventional Breast Solutions$375 M9.1%
  • Blood Screening$28 M0.7%
  • Other$19 M0.5%

Business segments

  • Diagnostics$1.8 B45%
  • Breast Health$1.5 B36%
  • GYN Surgical$680 M17%
  • Skeletal Health$109 M2.7%

Countries and regions

  • 🇺🇸 USA$3.0 B74%
  • International$1.1 B26%
  • Europe$591 M14%
  • Asia-Pacific$243 M5.9%
  • Rest of World$218 M5.3%

Source: SEC annual report (XBRL data) · as of Sep 27, 2025

Where Hologic, Inc. operates: 31 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 78 subsidiaries on file.

Present, no revenue figure for the countryShare of revenue reported there:under 10%10–25%25% or moreNothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
Hologic, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters3 offices19 subsidiaries$3.0 B74%
🇬🇧 UK9 subsidiaries—
🇧🇪 Belgium2 subsidiaries—
🇨🇳 China5 subsidiaries—
🇩🇪 Germany4 subsidiaries—
🇧🇲 Bermuda3 subsidiaries—
🇫🇮 Finland3 subsidiaries—
🇳🇱 Netherlands3 subsidiaries—
🇨🇭 Switzerland3 subsidiaries—
🇩🇰 Denmark2 subsidiaries—
🇫🇷 France2 subsidiaries—
🇭🇰 Hong Kong2 subsidiaries—
🇪🇸 Spain2 subsidiaries—
🇸🇪 Sweden2 subsidiaries—
🇦🇺 Australia1 subsidiary—
🇦🇹 Austria1 subsidiary—
🇧🇷 Brazil1 subsidiary—
🇻🇬 British Virgin Islands1 subsidiary—
🇨🇦 Canada1 subsidiary—
🇨🇷 Costa Rica1 subsidiary—
🇮🇳 India1 subsidiary—
🇮🇪 Ireland1 subsidiary—
🇮🇹 Italy1 subsidiary—
🇯🇵 Japan1 subsidiary—
🇲🇾 Malaysia1 subsidiary—
🇳🇴 Norway1 subsidiary—
🇵🇹 Portugal1 subsidiary—
🇸🇦 Saudi Arabia1 subsidiary—
🇸🇬 Singapore1 subsidiary—
🇰🇷 South Korea1 subsidiary—
🇹🇼 Taiwan1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Hologic, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 11 · Material agreement 3 · Agreement ended 1 · New debt 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11

Hologic, Inc.: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementAgreement endedShareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K/A
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Apr 7, 2026

Acquisitions and funding#

4 acquisitions, $669 M paid where reported

Businesses it acquired

Acquisitions by Hologic, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Gynesonics, Inc2025—$341 M—Annual report
Endomagnetics Ltd2024—$314 M—Annual report
Normedi2023—$8 M—Annual report
JW Medical2023—$7 M—Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Government contracts: Hologic, Inc.#

$3.5 M in federal contracts in fiscal 2026, mostly from Department of Veterans Affairs and Department of Defense.

Contracts, FY2026
$3.5 M
#408 among companies on value.today
Grants, FY2026
—
FY2027 to date
$63 K
contracts and grants
Since FY2008
$682.2 M
contracts and grants
  • Department of Veterans Affairs$3.1 M
  • Department of Defense$441 K
Hologic, Inc.: federal obligations by fiscal year
Fiscal yearContractsGrants
FY2027 (to date)$63 K—
FY2026$3.5 M—
FY2025$6.1 M—
FY2024$20.9 M—
FY2023$37.4 M—
FY2022$74.2 M—
FY2021$165.8 M—
FY2020$65.0 M—
FY2019$23.7 M—
FY2018$29.9 M—
FY2017$37.6 M—
FY2016$37.1 M—
FY2015$29.8 M—
FY2014$33.8 M—
FY2013$18.6 M—
FY2012$18.0 M—
FY2011$14.0 M—
FY2010$23.0 M—
FY2009$18.5 M—
FY2008$25.3 M—

Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Hologic, Inc.: HOLOGIC, INC. (UEI WHWJBKU5SX73)

Lobbying by Hologic, Inc.#

$1.2 M spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, trade (domestic/foreign) and manufacturing.

Lobbying, 2025
$1.2 M
#361 among companies on value.today
Own lobbyists
Yes
files its own reports
Firms hired
1
in 2025
2026 so far
$930 K
  • Health Issues8 reports
  • Trade (domestic/foreign)3 reports
  • Manufacturing2 reports
  • Budget/Appropriations2 reports
  • Medicare/Medicaid1 report

Lobbying firms hired in 2025

ALSTON & BIRD LLP $620 K

The firms' fees are part of Hologic, Inc.'s own reported expenses, so they are not added again.

Hologic, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$930 K$930 K6
2025$1.2 M$1.2 M8
2024$1.0 M$1.0 M10
2023$1.1 M$1.1 M12
2022$1.0 M$1.0 M21
2021$400 K—16
2020$290 K—12
2019$310 K—10
2018$240 K—8

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Hologic, Inc.”, “Capitol Counsel LLC on behalf of Hologic, Inc.” and “Burson Cohn & Wolfe on behalf of Hologic, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Hologic, Inc.#

32 labor condition applications certified in fiscal 2026 for 32 positions, at a median wage of $140 K a year.

Certified, FY2026
32
#426 among companies on value.today
Worker positions
32
Median wage offered
$140 K
a year, full-time
Applications filed
32
Hologic, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Electrical Engineer 3Electrical Engineers2$148 K
Lead Design Assurance EngineerValidation Engineers2$165 K
Quality Engineer 2Validation Engineers2$106 K
Demand Planner 3Transportation, Storage, and Distribution Managers1$106 K
Lead Software Design Assurance EngineerSoftware Quality Assurance Analysts and Testers1$155 K
Lead Software Engineer, Full StackSoftware Developers1$165 K
Lead Systems Engineer, R&DElectrical Engineers1$158 K
Lead Ultrasound EngineerBioengineers and Biomedical Engineers1$140 K
Manager, Software EngineeringSoftware Developers1$163 K
Medical Device Reporting SpecialistRegulatory Affairs Specialists1$106 K

Where: Newark, DE 16 · Marlborough, MA 12 · Louisville, CO 1 · Killeen, TX 1 · Ellicott City, MD 1 · Denville, NJ 1

Hologic, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY20263232$140 K32
FY20253131$121 K31
FY20242121$120 K21
FY20231414$130 K15
FY20223434$125 K34
FY20212727$105 K27
FY20202020$118 K21

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Hologic, Inc.

Product recalls by Hologic, Inc.#

36 recalls since 2015, 847,509 units in the notices that give a number. Medical devices (FDA): 36.

Hologic, Inc.: product recalls
DateWhat and whyUnitsNotice
SELENIA DIMENSIONS MAMMOGRAPHY SYSTEMS. Model Numbers: SDA-SYS-3000-2D-HTC, SDA-SYS-3000-3D, SDM-SYS-6000-2D, SDM-SYS-6000-3D, SDM-00001-2D, SDM-00001-3D, SDM-00001-M2D, SDM-00001-M3D, SDM-05000-2A2, SDM-05000-2A3, SDM-05000-2AC, SDM-05000-2D2, SDM-05000-2D3, SDM-05000-2DC, SDM-05000-3D2, SDM-05000-3D3, SDM-05000-3DC, SDM-SYS-9… (and 1 more products)Complaints have been received of systems developing loose, missing, or broken internal bolts over time.Medical devicesClass II4,305Z-2167-2026
Brand Name: Genius" Review Station Product Name: Genius" Review Station Display (Barco Monitor) Model/Catalog Number: CMP-01669 Software Version: N/A - not software version specific Component: Yes, the Genius" Review Station is a component of the Genius" Digital Diagnostics System with the Genius" Cervical AI Algorithm cleared…It was identified that certain devices were being operated outside the validated and FDA-cleared display configuration due to user modification of the manufacturer-installed settings. Modifications included disabling Barco Application Appearance Manager (AAM), altering calibration and compliance parameters, and adjusting additional display-related settings. This field correction is being conducted to restore affected system to the validated configuration and reinforce proper use in accordance with the Operator's Manual.Medical devicesClass II1,200Z-1949-2026
Brand Name: Aptima HPV Assay Product Name: Aptima HPV Assay Model/Catalog Number: 303585 Product Description: Aptima HPV assay Component: NoDue to product exhibiting potential to generate either invalid or false negative results.Medical devicesClass II306Z-1586-2026
Brevera Breast Biopsy System Disposable 9 Gauge Needle. Biopsy Instrument.Presence of particulates in affected devices that can be deposited into breast tissue during use.Medical devicesClass II681,870Z-1314-2026
ThinPrep¿ CytoLyt¿ Solution. Buffered Cell Wash Solution.Fungal contamination of affected lot with Parengyodontium album.Medical devicesClass II3,728Z-1093-2026
Brand Name: Sertera Biopsy Device Product Name: Sertera Biopsy Device Model/Catalog Number: Sertera-14 Software Version: N/A Product Description: Instrument, Biopsy Component: N/ADevices presented a condition in which the inner needle separated from the hub and produced a longer throw of the inner needle or dislodgement.Medical devicesClass II55,335Z-1170-2025
The Rapid fFN Specimen Collection Tube (PN: 71550-001) is a component of the Rapid fFN Specimen Collection kit (PN: 71738-001). The Collection Tube (PN: 71550-001) is manufactured by a third-party supplier, MML Diagnostics Packaging, and includes the transport tube, cap, and extraction buffer. Tubes are packaged into PN: 71738-…Three lots of Rapid fFN Specimen Collection kit (901164, 901165, and 904850) contain Rapid fFN Specimen Collection Tubes which may be empty, underfilled, or overfilled with extraction buffer. The transport tubes are used with the Fetal Fibronectin Enzyme Immunoassay and Rapid fFN¿ for the TLiIQ¿ System which aids in assessing the risk of preterm delivery. The use of empty transport tubes or transport tubes containing insufficient extraction buffer volume may result in invalid results and/or delays in obtaining results. Additionally, the use of underfilled tubes may result in false positive results and the use of overfilled tubes may result in false negative results.Medical devicesClass II1,351Z-1095-2025
Panther Fusion GBS Assay REF PRD-04484 Kit containing Panther Fusion GBS Reagent Cartridge IVD.Potential weak pouch seal on Panther Fusion GBS assay cartridge, causing potential for invalid or incorrect results leading to a possible delay of treatment.Medical devicesClass II380Z-0907-2025
Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay, REF: PRD-07400SARS-CoV-2/Flu A/B/RSV Assay Kit may erroneously produce SARS-CoV-2 false positive results.Medical devicesClass II3Z-0694-2025
BioZorb Marker. Radiographic soft tissue marker.Firm received reports of adverse events/complications that include serious injuries, such as pain, infection, rash, device migration, device erosion, seroma, and discomfort.Medical devicesClass I12,710Z-0328-2025
Selenia Dimensions/ 3Dimensions-Digital breast tomosynthesis Software Version Dimensions 1.12.0 and 3Dimensions 2.3.0 system software as follows Model/Catalog Number: 1. ASY-16824 FMI UPGRADE KIT, DIMENSIONS 1.12.0.3 SYSTEM SOFTWARE UPGRADE FOR 1.11.1 SYSTEMS 2. ASY-16825 FMI UPGRADE KIT, 3DIMENSIONS 2.3.0.3 SYSTEM SOFTWARE UPG…Identified an issue with Selenia Dimensions 1.12.0 and 3Dimensions 2.3.0 system software when used in combination with C-View software in which the quality of the final C-View synthesized 2D image is impacted and may appear blurry and result in misdiagnosis with the possibility being a false negative diagnosisMedical devicesClass II425Z-3248-2024
Horizon X-Ray Bone Densitometer (DXA) Models: Horizon-A, Horizon-W, Horizon-WI, Horizon-C, Horizon-CI, Horizon-A-CN, Horizon-W-CN, Horizon-WI-CN, Horizon-CI-CNNon-conformance pertains to electromagnetic compatibility requirements according to the international technical standard IEC 60601-1-2 for the safety and essential performance of medical electrical equipment, where the result from the Horizon DXA System exceeded the limit for acceptability.Medical devicesClass II2,642Z-2373-2024
BioZorb Marker-BioZorb 3D Bioabsorbable Marker-Intended Use radiographic marking of sites in soft tissue. 1) F0405 BioZorb Marker 4cm x 5cm 2) F0404 BioZorb Marker 4cm x 4cm 3) F0331 BioZorb Marker 1cm x 3cm x 3cm 4) F0231 BioZorb Marker 1cm x 3cm x 2cm 5) F0221 BioZorb Marker 1cm x 3cm x 2cm 6) F0304 BioZorb Marker 3cm x 4cm 7…Safety Information: Complaints describe complications/adverse events that include pain, infection, rash, device migration, device erosion, seroma, discomfort, or other complications from feeling the device in the breast, and the need for additional medical treatment to remove the deviceMedical devicesClass I53,492Z-1733-2024
PANTHER FUSION System REF 9121010000 The Panther System is an integrated nucleic acid testing system which fully automates all steps necessary to perform Aptima assays from sample processing through amplification, detection, and data reduction. The Panther Fusion System is an integrated, fully automated, in vitro diagnostic (IV…Due to potential false positive Flu B results when a sample was also SARS-CoV-2 positive.Medical devicesClass II771Z-0782-2024
Aptima CMV Quant Assay, Reference numbers: AW-22600-001, AW-25509-001, and AW-26381-001 Amplification Reagent, Enzyme Reagent, Promoter Reagent, Amplification Reconstitution Solution, Enzyme Reconstitution Solution, Promoter Reconstruction solution, Target capture Reagent, Reconstitution Collars.Use of assay along with plasma specimen may result in error code which would invalidate sample.Medical devicesClass II684Z-1371-2024
Sertera 14 Gauge Biopsy Device-intended to obtain percutaneous core biopsy samples from soft tissue and tumors of the breast REF: SERTERA-14The inner needle of the Sertera device is either detaching or discharging and may cause delay in surgeryMedical devicesClass II756Z-2035-2023
Hologic 3Dimensions/Selenia Dimensions Models: RM-SDM-00001-3D SDM-00001-2D SDM-00001-3D SDM-05000-3D3 SDM-05000-2DC SDM-00001-M3D SDM-05000-3DC SDM-SYS-6000-3D SDM-05000-2D3 SDA-SYS-3000-2D SDM-00001 SDM-SYS-9000-2D SDM-00001-M2D 3DM-SYS-STD 3DM-SYS-STD-NS SDM-05000-2AC SDM-05000-2A2 SDA-SYS-3000-3D SDA-SYS-3000-3D-UPS SDM-SYS…C-Arm unexpected movement may cause blunt trauma should the tube arm impinge upon an individualMedical devicesClass II797Z-1144-2023
Hologic Sizer Set- sterilization tray and 6 individual sizers, intended as a Surgical instrument guide Model/Catalog Number: F0101IFU was not provided with the Sizer Set sterilization tray Revised Sterilization Instructions for Sizer SetMedical devicesClass II178Z-0669-2025
The BioZorb LP Marker is an implantable radiopaque marker used to facilitate visualization of a soft tissue site. The BioZorb LP Marker is comprised of a bioabsorbable PLA (polylactic acid) component which resorbs completely in 1 year or more and a permanent component (titanium). The BioZorb LP Marker is provided sterile for si…Hologic BioZorb LP Marker, (Product number F0221), lot number 22A0RL, contained removable labels with an expiration date that indicated the product had already expired. The expiration date on the removable label is actually manufacturing date, and it's different from the one on the shelf box label, which is the correct expiration date.Medical devicesClass II233Z-1858-2022
Panther Fusion GBS Assay Cartridges 96 Tests, Catalog Number: PRD-04484. in vitro diagnostic test for group b streptococcus.Samples, run on a GBS Assay, that have analyte concentrations that are at or near the limit of detection may produce false negative results.Medical devicesClass II2,061Z-0877-2022
Panther Fusion Extraction Reagent-X, REF PRD-04477, For use with Panther Fusion System, IVD, Rx only, Contents: FCR-X Fusion Capture reagent-X 4 EA, FER-X Fusion Enhancer Reagent-X (Lithium Hydroxide Solution) 4 EAFailed stability specifications for reagent kits that may result in false negative test results.Medical devicesClass II264Z-0750-2022
Panther Fusion Tube Tray, REF PRD-04000, PN: FA-15004, Cont. 18 Tube Trays - Product Usage: an ancillary consumable to the Panther Fusion System that is used to contain the PCR and RT-PCR steps of the assay processing.There is a potential for tube trays to leak which could potentially result in false positive results, false negative results or invalid patient results.Medical devicesClass II1,355Z-1369-2021
Panther Fusion Tube Tray, Part: FAB-15004, REF: PRD-04000Tube trays may leak which could invalidate patient results or assay worklists, causing delayed results for any assays with which they are used. A possibility exists of false negative result with flu A/B/RSV assay or paraflu assay.Medical devicesClass II607Z-2990-2020
Selenia Dimensions Mammography System, Model number ASY-04160, Selenia Dimensions Gantry, UDI 15420045505636,The recalling firm has received reports from the field of the C-arm on the Selenia Dimensions system seizing or dropping during field repairs and cleaning of the systems.Medical devicesClass II72Z-1343-2020
Panther Fusion Extraction Reagent-S, Ref PRD-04331, IVD, CE, Rx Only consisting of FCR-S Fusion Capture Reagent - S, Nucleic Acid in a buffered solution and FER-S Fusion Enhancer Reagent-S (Lithium Hydroxide Solution), UDI: 15420045509214Reagent component included in flu test kit may cause both high background signal in a true negative sample leading to false positive and/or false negative results. This could result in false positive and/or false negative results on patient samples or failed controls leading to invalid runs. This could result in incorrect results being reported and a delay in treatment.Medical devicesClass II47Z-2163-2020
I-View¿ Contrast Enhanced Digital Mammography, ASY-08109Calibration issue not possible to visualize contrast uptake in the subtracted mammography imagesMedical devicesClass II337Z-0685-2019
Hologic Panther(R) Fusion(TM), Catalog number ASY-09600 Product Usage: The Panther instrument is a fully automated sample-to-result instrument, eliminating the need for batch processing and automates all aspects of nucleic acid testing on a single, integrated platform. The Panther can be test samples with random access or batch…The Panther or the Panther Fusion glass panel separates from the 19 inch touch screen monitor and could potentially fall and hit an operator.Medical devicesClass II103Z-0595-2018
Rapid for the TLiIQ(R) System, HOLOGIC(R), Catalog number: 01200 (and 1 more products)Rapid fFN cassettes were manufactured with material (A137 ascites) from a new supplier (SDIX). The products were distributed to customers before FDA approved the change to use the material from SDIX.Medical devicesClass II165Z-0676-2018
Panther(R) System, Catalog Number 902615, For Use with Hologic Assays, For In Vitro Diagnostic UseAn incorrect incubator was installed on one Panther System which potentially led to incorrect Aptima Combo 2(R) assay (AC2) results.Medical devicesClass II1Z-0027-2018
Affirm Lateral Arm Upright Biopsy Accessory. Product Number: ASY-09880The firm is implementing a product correction involving its Affirm¿ Lateral Arm Upright Biopsy Accessory, ASY-09880. The correction has been initiated due to a component (the Left-hand Guide or the Blue Needle Guide) issue that could impact needle alignment for all the left-approach lateral biopsy procedures. This may have an impact on the position of the needle within the breast, and thus on the aspiration of the intended tissue. This impact is case-dependent and detectable when imagining is used to confirm needle position and/or tissue acquisition during and after a procedure. There are no known instances of illness or injury.Medical devicesClass II12Z-0351-2018
Tomcat Instrument, REF ASY-07379, Hologic Incorporated, automated laboratory sample processing instrument.A Tomcat Instrument software anomaly that causes the pipettor arm to make physical contact with the mucous shelf which could potentially lead to incorrect patient results.Medical devicesClass II164Z-2864-2017
SURESOUND22US Multipack (US Distribution) containing 2 packs of six devices. SURESOUND22 Multipack (OUS Distribution) containing 2 packs of six devices. For uterine soundBreach in sterile barrier compromising product sterilityMedical devicesClass II600Z-0655-2017
Sertera Biopsy Device, Sterile; Used primarily in ultrasound-guided breast biopsies.Incorrect label on the Sertera Biopsy KitMedical devicesClass II570Z-2869-2016
SureSight Obturator Introducer Localization Systems (ILS) for ATEC in MRI. ILS-0914-12-OB (9G Introducer Localization Set (OB Model) for ATEC0914-12MR Handpiece Product Usage: The Sure Sight Obturator Introducer Localization System (ILS-OB) is a Hologic accessory kit. It is sold as an independent product for use with the ATEC M… (and 1 more products)Tip Breakage at the glue joint between the obturator body and tipMedical devicesClass II535Z-2766-2016
ATEC CANISTER. Suction Canister with Lid 490 cc., RX Only; Suction canister used to collect fluid during a breast biopsy.Cracks ATEC Canister Lids.Medical devicesClass II16,870Z-2239-2016
Hologic InPlex CF Molecular Test (IVD); Catalog Number: 95-432. (and 1 more products)Complaints of false positive HET mutations and leaking cards; could lead to unnecessary invasive testing during pregnancy and the associated risks of such invasive testing.Medical devicesClass II2,580Z-1580-2016

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Layoffs at Hologic, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
93
2020–2020
Latest
93 people
2020-04-10
Hologic, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020···93········93
Hologic, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
effective 93 peopleLayoff, temporaryWARN noticeSan Diego County, CaliforniaNotice list

Source: State WARN notices and SEC 8-K item 2.05

How Hologic, Inc. compares in Medical Instruments

  • Revenue$4.1 B · higher than 89% of 120
  • Net margin13.2% · higher than 65% of 114
  • Revenue growth1.7% · higher than 21% of 49

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Hologic, Inc.🇺🇸$16.9 B—13.2%+1.7%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Mar 8, 2026 (last known)
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Employees:
As on 2022
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Hologic, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Hologic, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Hologic, Inc.? Suggest a correction